Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy

PURPOSE: Immune checkpoint inhibitors have opened a new scenario in the treatment of cancer. These agents can elicit adverse events, which may affect different systems and organs, including the endocrine system. The aims of this study were to evaluate the impact of the anti-PD-1 molecules nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubino, Rossella, Marini, Andrea, Roviello, Giandomenico, Presotto, Elena Margherita, Desideri, Isacco, Ciardetti, Isabella, Brugia, Marco, Pimpinelli, Nicola, Antonuzzo, Lorenzo, Mini, Enrico, Livi, Lorenzo, Maggi, Mario, Peri, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440282/
https://www.ncbi.nlm.nih.gov/pubmed/34036513
http://dx.doi.org/10.1007/s12020-021-02750-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440282/
https://www.ncbi.nlm.nih.gov/pubmed/34036513
http://dx.doi.org/10.1007/s12020-021-02750-w

Ejemplares similares